NeuroSense Therapeutics Ltd.

Healthcare · Biotechnology · Israel

Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical stu...